|
|
Post by Clement on Jul 30, 2023 6:33:24 GMT -5
I don’t remember the exact percentage of Tyvaso DPI test subjects at the end of the test elected to continue on the DPI formulation but I think it was close to 100%. The conversion rate may be similar and the conversion sales process similar to saying something like “Your patients will most likely prefer DPI because that’s been the response, and that should hopefully result in better outcomes”. The conversion rates seem to be dictated by when patients have their doctor visits, so I’m guessing the 40% increase we saw between 4Q and 1Q is going to be the rate we see for 2Q to 1Q.
I believe it is very easy to predict MNKD Tyvaso DPI revenue from UTHR 10q. Example last quarter
UTHR 10q 1st quarter 11. Segment Information
cost of Tyvaso sales 26.9 mil
MNKD 10q 1st quarter 10. Collaboration, Licensing and Other Arrangements Total revenue from UT (both CSA and UT License Agreement 11.3M and royalties 11.7m) $23m
Mike said on one of the calls CSA will stabilize to about 9 mil a quarter the the rest will be royalty growth. There is also the chance for some of the deferred income to be recognized that will skew this, but hopefully will be labeled as such so that we can calculate growth with the royalty increase.
Serious question. Since that 26.9 M cost of sales is for total Tyvaso (both Tyvaso-neb and Tyvaso DPI), how do you get from there to 23M MNKD TDPI revenue? TIA. |
|
|
|
Post by prcgorman2 on Jul 30, 2023 10:45:57 GMT -5
I don’t remember the exact percentage of Tyvaso DPI test subjects at the end of the test elected to continue on the DPI formulation but I think it was close to 100%. The conversion rate may be similar and the conversion sales process similar to saying something like “Your patients will most likely prefer DPI because that’s been the response, and that should hopefully result in better outcomes”. The conversion rates seem to be dictated by when patients have their doctor visits, so I’m guessing the 40% increase we saw between 4Q and 1Q is going to be the rate we see for 2Q to 1Q.
I believe it is very easy to predict MNKD Tyvaso DPI revenue from UTHR 10q. Example last quarter
UTHR 10q 1st quarter 11. Segment Information
cost of Tyvaso sales 26.9 mil
MNKD 10q 1st quarter 10. Collaboration, Licensing and Other Arrangements Total revenue from UT (both CSA and UT License Agreement 11.3M and royalties 11.7m) $23m
Mike said on one of the calls CSA will stabilize to about 9 mil a quarter the the rest will be royalty growth. There is also the chance for some of the deferred income to be recognized that will skew this, but hopefully will be labeled as such so that we can calculate growth with the royalty increase.
Clement and I saw the same thing. I also wonder what is the ~$4M in difference between “cost of Tyvaso sales” and “Total revenue from UT”? Cost of Treprostinil? Seems too obvious. Good observation anderson. A correlation for us to continue to watch! |
|
|
|
Post by anderson on Jul 30, 2023 15:12:32 GMT -5
I believe it is very easy to predict MNKD Tyvaso DPI revenue from UTHR 10q. Example last quarter
UTHR 10q 1st quarter 11. Segment Information
cost of Tyvaso sales 26.9 mil
MNKD 10q 1st quarter 10. Collaboration, Licensing and Other Arrangements Total revenue from UT (both CSA and UT License Agreement 11.3M and royalties 11.7m) $23m
Mike said on one of the calls CSA will stabilize to about 9 mil a quarter the the rest will be royalty growth. There is also the chance for some of the deferred income to be recognized that will skew this, but hopefully will be labeled as such so that we can calculate growth with the royalty increase.
Serious question. Since that 26.9 M cost of sales is for total Tyvaso (both Tyvaso-neb and Tyvaso DPI), how do you get from there to 23M MNKD TDPI revenue? TIA. I would suspect the $3 mil difference is the cost of the API since UTHR would have to buy that somewhere or manufacture it. |
|
|
|
Post by agedhippie on Jul 31, 2023 8:40:39 GMT -5
I would suspect the $3 mil difference is the cost of the API since UTHR would have to buy that somewhere or manufacture it. I wonder if anything can be inferred from that. If one process used more than the other you might be able to roughly work out a ratio by looking at the revenue to cost ratio. |
|
|
|
Post by wyattdog on Jul 31, 2023 15:01:57 GMT -5
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 31, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2023 second quarter financial results and year to date financial results and its management will host a conference call to discuss these results and corporate updates at 5:00 PM (Eastern Time) on Monday, August 7, 2023. Presenting from the Company will be its Chief Executive Officer, Michael Castagna and Chief Financial Officer, Steven Binder. Those interested in listening to the conference call live via the Internet may do so by visiting the Company's website at investors.mannkindcorp.com/events-and-presentations under Events & Presentations. About MannKind Corporation MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung disease. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life. Please visit mannkindcorp.com to learn more, and follow us on LinkedIn, Facebook, Twitter or Instagram. For MannKind: Rose Alinaya, Investor Relations (818) 661-5000 Email: ir@mannkindcorp.com |
|
|
|
Post by runner on Jul 31, 2023 15:08:50 GMT -5
I’m looking forward to this call.
|
|
|
|
Post by castlerockchris on Jul 31, 2023 15:45:41 GMT -5
For the 40 or 50 something time, so am I! 😝
|
|
|
|
Post by tarheelblue004 on Jul 31, 2023 16:28:21 GMT -5
UT Wednesday, MKND Monday...let Quarterly Super Bowl week commence!
|
|
|
|
Post by veritasfiliatemporis on Aug 2, 2023 5:57:42 GMT -5
United Therapeutics Corporation Reports Second Quarter 2023 Financial Results......"From Net product sales from our treprostinil-based products (Tyvaso, Remodulin, and Orenitram) grew by $129.2 million, or 31%, for the second quarter of 2023, as compared to the second quarter of 2022. The growth in Tyvaso revenues resulted primarily from an increase in quantities sold to our domestic distributors of $112.0 million. $96.9 million of this growth resulted from an increased number of patients following the commercial launch of Tyvaso DPI in June 2022 and continued growth in the number of patients following the Tyvaso label expansion in March 2021 to include the treatment of pulmonary hypertension associated with interstitial lung disease."
|
|
|
|
Post by Clement on Aug 2, 2023 6:41:52 GMT -5
UTHR has reported:
UTHR Total Tyvaso Q2.... 318.9M net revenue
UTHR Total Tyvaso Q1.... 238.4M " "
That's an increase of 33.7% QoQ.
Assuming sales to patients of TDPI increased at same rate as total Tyvaso, 1.337 x (Q1 MNKD royalties) = 15.6M in royalties to MNKD for Q2.
|
|
|
|
Post by tarheelblue004 on Aug 2, 2023 6:56:21 GMT -5
The quarter over quarter numbers are even more impressive!
Q1 Tyvaso Revenue: $238.4m
Q2 Tyvaso Revenue: $318.9m
Difference: $80m increase!
Q1 Cost of Sales: $52.7m
Q2 Cost if Sales: $63.2m
Difference: $10.5m increase!
I have no choice but to up my estimates for MannKind Q2. $50m revenue MINIMUM, not including growth in Afrezza (dark horse) or V-Go. That is 25% QoQ growth and a 20% beat of Analyst estimates ($42M). It puts us right at the edge of profitability!! And it almost feels conservative to me, as Afrezza sales do seem to be growing.
Then I expect Q3, with an entire quarter of tripled Tyvaso production, to blow Q2 out of the park and raise the bar even more!
|
|
|
|
Post by anderson on Aug 2, 2023 8:17:57 GMT -5
I believe it is very easy to predict MNKD Tyvaso DPI revenue from UTHR 10q. Example last quarter
UTHR 10q 1st quarter 11. Segment Information
cost of Tyvaso sales 26.9 mil
MNKD 10q 1st quarter 10. Collaboration, Licensing and Other Arrangements Total revenue from UT (both CSA and UT License Agreement 11.3M and royalties 11.7m) $23m
Mike said on one of the calls CSA will stabilize to about 9 mil a quarter the the rest will be royalty growth. There is also the chance for some of the deferred income to be recognized that will skew this, but hopefully will be labeled as such so that we can calculate growth with the royalty increase.
UTHR 10q 2nd quarter 11. Segment Information Cost of tyvaso sales 40.4 13.5 mil more than last quarter. I would hope mnkd total revenue from UT will be around $33m |
|
|
|
Post by Thundersnow on Aug 2, 2023 23:58:49 GMT -5
Has MNKD ever released earnings on a MONDAY?? I don't think so!!!
Hoping for a nice surprise on Monday!
|
|
|
|
Post by cppoly on Aug 3, 2023 5:41:18 GMT -5
Anybody catch on UTHR's call that 70% of new patients are going with DPI
|
|
|
|
Post by sayhey24 on Aug 3, 2023 6:25:50 GMT -5
Has MNKD ever released earnings on a MONDAY?? I don't think so!!! Hoping for a nice surprise on Monday! Me too. I thought the same when it was announced and the day before he goes to the old Helmsley Palace in NYC. Hope springs eternal but its MNKD so I usually prepare for the worst. |
|
